泌乳素瘤与Knosp分级:何时手术是合适选择?系统综述与荟萃分析
Knosp 0-2级生化缓解率为75%(95%CI 67%-82%),Knosp 3-4级为22%(95%CI 16%-31%)。经蝶手术并发症率低且无死亡报告,支持对Knosp 0-2级患者考虑手术作为一线治疗。
要点
- Knosp 0-2级泌乳素瘤经蝶手术生化缓解率为75%(95%CI 67%-82%)。
- Knosp 3-4级泌乳素瘤经蝶手术生化缓解率为22%(95%CI 16%-31%)。
- 经蝶手术并发症率低且无死亡报告,支持在高水平中心对合适患者考虑手术。
核心结论
- Knosp 0-2级泌乳素瘤切除作为一线治疗可能有效,生化缓解率良好且并发症风险低。
- 研究结果支持在经验丰富的医疗中心对适当选择的患者考虑手术。
- 纳入研究的高异质性和观察性设计限制了结论强度,需进一步比较手术与药物治疗并优化患者选择。
研究设计与样本
- 系统综述与荟萃分析,检索MEDLINE、Scopus、Web of Science、LILACS和Cochrane CENTRAL数据库自建库至2024年2月。
- 采用随机效应荟萃分析合成生化缓解率和相对风险,按Knosp分级进行亚组分析,使用I2统计量评估异质性,报告预测区间,通过漏斗图和Egger检验评估发表偏倚。
- 研究注册于PROSPERO(注册号CRD42024602904),遵循PRISMA指南。
主要发现
- Knosp 0-2级泌乳素瘤生化缓解率为75%(95%CI 67%-82%,预测区间42%-96%,I2=81.5%,p<0.0001)。
- Knosp 3-4级泌乳素瘤生化缓解率为22%(95%CI 16%-31%,预测区间11%-38%,I2=17.2%,p=0.57)。
- 经蝶手术并发症率低,无死亡报告。
关键数值与推荐
- Knosp 0-2级泌乳素瘤经蝶手术生化缓解率75%(95%CI 67%-82%)。
- Knosp 3-4级泌乳素瘤经蝶手术生化缓解率22%(95%CI 16%-31%)。
- 2023年垂体学会指南推荐手术作为特定泌乳素瘤(尤其特定Knosp分级)的一线选择。
临床怎么用
- 对Knosp 0-2级泌乳素瘤患者,可考虑将经蝶手术作为一线治疗选项。
- 手术决策应在经验丰富的医疗中心进行,并针对适当选择的患者。
- Knosp 3-4级患者手术生化缓解率较低,需权衡手术与药物治疗。
局限性
- 纳入研究间存在高异质性(如Knosp 0-2级I2=81.5%)。
- 多数纳入研究为观察性设计,限制了结论强度。
- 需进一步研究比较不同Knosp分级下手术与药物治疗策略并优化患者选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Prolactinomas are the most common type of pituitary adenoma. Historically, surgery was the primary treatment, but the introduction of dopaminergic agonists in the 1970s changed therapeutic practices. Recent guidelines (2023) from the Pituitary Society now recommend surgery as the first-line option for select prolactinomas, particularly those with certain grades as defined by the Knosp classification system. This systematic review and meta-analysis was performed to evaluate the safety of and the biochemical remission rates following resection of prolactinomas classified preoperatively by Knosp grade. METHODS: A comprehensive literature search was conducted across the MEDLINE (via PubMed), Scopus, Web of Science, LILACS (Latin American and Caribbean Literature on Health Sciences), and Cochrane CENTRAL (Central Register of Controlled Trials) databases from inception to February 2024. Eligible studies reported individual participant data on the biochemical remission and surgical outcomes of patients with prolactinomas stratified by Knosp grade. A random effects meta-analysis was performed to synthesize biochemical remission rates and relative risks, with results presented in forest plots. Subgroup analyses were conducted according to Knosp grade, heterogeneity was assessed using the I2 statistic, prediction intervals were reported, and publication bias was evaluated through funnel plots and Egger's test. This review was registered in the International Prospective Register of Systematic Reviews (registration no.: CRD42024602904) and followed the PRISMA guidelines. RESULTS: Twelve studies involving 1010 patients with prolactinomas undergoing transsphenoidal surgery were included. Prolactinomas classified as Knosp grades 0-2 demonstrated significantly higher biochemical remission rates of 75% (95% CI 67%-82%, prediction interval 42%-96%, I2 = 81.5%, p < 0.0001) compared to 22% (95% CI 16%-31%, prediction interval 11%-38%, I2 = 17.2%, p = 0.57) for Knosp grades 3-4. Transsphenoidal surgery was associated with favorable outcomes characterized by low complication rates and no reported deaths. CONCLUSIONS: Resection for Knosp grade 0-2 prolactinomas appears to be an effective first-line treatment option, resulting in favorable biochemical remission rates and low complication risks. These findings support considering surgery in appropriately selected patients, particularly at experienced medical centers. However, the high heterogeneity among and the observational design of most included studies limit the strength of the conclusions. Thus, further studies are needed to compare surgical and medical management strategies across Knosp grades and to refine patient selection.
引用
- Ordoñez-Cure S, Uparela-Reyes MJ, Cardona-Collazos S, et al. Prolactinomas and Knosp grade: when is surgery the appropriate choice? A systematic review and meta-analysis. J Neurosurg. 2025. PMID: 40939216. doi:10.3171/2025.5.JNS243092
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。